stockrow
Friday 6 November 2026
Export CTKB’s income statement to Excel — free account
Cytek Biosciences, Inc.
CTKB Healthcare Medical Devices
Cytek Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $201.5 million, up 0.52% from fiscal 2024.
- Revenue
- +1.79%
- EPS
- −17.0%
- Free cash flow
- −30.3%
- Total debt
- −84.9%
Quarter to September 2026, against a year earlier
5.82
0.42
+7.78%
Follow CTKB
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
3.20 | 2.75 | 2.77 | 3.74 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(836.73) | (205.57) | 419.54 | (174.55) | |
P/B ratio |
1.89 | 1.72 | 1.78 | 2.42 | |
Price to Tangible BV |
2.09 | 1.91 | 1.97 | 2.67 | |
EV/Sales |
1.91 | 1.47 | 1.51 | 2.51 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(81.97) | (41.20) | (51.63) | (79.01) | |
EV/FCF |
(44.54) | (23.83) | (26.05) | (39.03) | |
Quick Ratio |
4.16 | 3.88 | 3.70 | 3.71 | |
Current Ratio |
5.04 | 4.69 | 4.48 | 4.46 | |
Net Debt/EBITDA |
102.35 | 16.73 | 31.11 | 48.22 | |
Debt/Assets |
0.11% | 0.09% | 0.06% | 0.02% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.42 | 0.44 | 0.44 | 0.44 | |
Operating CF/Net income |
0.02 | 0.15 | (0.11) | 0.73 | |
Capex/Depreciation |
(0.28) | (0.78) | (0.75) | (0.48) | |
Interest Coverage |
7.71 | (70.47) | (40.57) | (32.40) | |
Research and Development Expense of Revenue |
14.42% | 21.76% | 20.23% | 17.58% | |
Selling, General and Administrative Expense of Revenue |
47.50% | 68.23% | 62.32% | 56.88% | |
Intangible Assets out of Total Assets |
0.07 | 0.07 | 0.07 | 0.07 | |
Share Based Compensation of Revenue |
8.89% | 11.01% | 11.09% | 9.12% | |
Graham Net Nets |
0.42 | 0.46 | 0.44 | 0.33 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(10.10%) | (13.04%) | (14.00%) | (10.52%) | |
Free Cash Flow Yield |
(1.34%) | (2.24%) | (2.09%) | (1.72%) | |
Revenue per Share |
0.49 | 0.34 | 0.37 | 0.41 | |
Operating CF per Share |
(0.01) | (0.02) | 0.01 | (0.03) | |
Capex per Share |
(0.01) | (0.02) | (0.02) | (0.01) | |
Free Cash Flow per Share |
(0.01) | (0.04) | (0.01) | (0.05) | |
Cash per Share |
2.05 | 2.04 | 2.02 | 1.97 | |
Shareholders Equity per Share |
2.68 | 2.55 | 2.49 | 2.47 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.68 | 2.55 | 2.49 | 2.47 | |
Free Cash Flow |
(1.61) | (4.93) | (0.87) | (5.93) | |
Working Capital |
314.19 | 298.37 | 293.60 | 293.98 | |
Capital Expenditures |
(0.84) | (2.19) | (2.24) | (1.48) | |
Net Current Asset Value |
272.19 | 257.83 | 252.95 | 254.14 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.05 | 0.05 | 0.03 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
61.55 | 53.47 | 52.97 | 57.91 | |
Average Payables |
5.97 | 6.49 | 7.63 | 6.26 | |
Average Inventory |
46.16 | 47.57 | 50.87 | 52.01 | |
Average Assets |
480.52 | 465.85 | 470.13 | 470.53 | |
Average Common Equity |
368.74 | 353.63 | 349.76 | 349.96 |
Columns are period end dates · fundamentals updated 6 Nov 2026